Literature DB >> 6360927

Thymopentin (TP-5) potency in vivo is enhanced by slow infusion.

T Audhya, G Goldstein.   

Abstract

The in vivo activity of thymopentin in guinea pigs was assessed electromyographically 18 h after intravenous or subcutaneous injections or infusions ranging over varying periods of time. The lowest threshold dose required to establish a positive effect was obtained with a 30-60 min i.v. infusion (0.38-0.75 micrograms/kg) and we found that we needed X 5 times this dose with 30 min s.c. infusion, X 10 this dose with 10 min i.v. or s.c. infusion, X 200 this dose with bolus IV injection and X 400 this dose with bolus s.c. injection. The marked increase of potency of thymopentin with infusion should be considered in designing clinical regimens.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6360927     DOI: 10.1111/j.1399-3011.1983.tb02130.x

Source DB:  PubMed          Journal:  Int J Pept Protein Res        ISSN: 0367-8377


  7 in total

Review 1.  Immunomodulation with thymopentin: in vitro studies.

Authors:  J Duchateau; K Bolla
Journal:  Med Oncol Tumor Pharmacother       Date:  1989

2.  Thymopentin-loaded phospholipid-based phase separation gel with long-lasting immunomodulatory effects: in vitro and in vivo studies.

Authors:  Ting Zhang; Xian-Yan Qin; Xi Cao; Wen-Hao Li; Tao Gong; Zhi-Rong Zhang
Journal:  Acta Pharmacol Sin       Date:  2018-07-12       Impact factor: 6.150

3.  Thymopentin: stability considerations and potency by various routes of administration.

Authors:  T K Audhya; G Goldstein
Journal:  Surv Immunol Res       Date:  1985

4.  Effect of subcutaneous thymopentin treatment in drug addicts with persistent generalized lymphadenopathy.

Authors:  W Barcellini; P L Meroni; D Frasca; C Sguotti; M O Borghi; C Uberti-Foppa; P Buzzetti; A Lazzarin; G Doria; M Moroni
Journal:  Clin Exp Immunol       Date:  1987-03       Impact factor: 4.330

5.  In vitro influence of thymopentin on proliferative responses and phytohemagglutinin-induced interleukin 2 production in normal human lymphocyte cultures.

Authors:  J Duchateau; G Servais; R Cooman; H Collet; K Bolla
Journal:  Surv Immunol Res       Date:  1985

6.  Thymopentin treatment in AIDS and pre-AIDS patients.

Authors:  N Clumeck; S Cran; P Van de Perre; F Mascart-Lemone; J Duchateau; K Bolla
Journal:  Surv Immunol Res       Date:  1985

7.  Some observations on various dose regimens of thymopentin treatment in rheumatoid arthritis.

Authors:  L Molin; F Schmid; K Bolla
Journal:  Surv Immunol Res       Date:  1985
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.